Filing Details

Accession Number:
0001209191-22-010918
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-02-17 17:39:14
Reporting Period:
2022-02-15
Accepted Time:
2022-02-17 17:39:14
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1805890 Fusion Pharmaceuticals Inc. FUSN Biological Products, (No Disgnostic Substances) (2836) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1813574 John Valliant C/O Fusion Pharmaceuticals, Inc.
2 International Place, Suite 2310
Boston MA 02110
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2022-02-15 12,600 $8.33 519,334 No 4 S Direct
Common Stock Disposition 2022-02-16 33,202 $7.99 486,132 No 4 S Direct
Common Stock Disposition 2022-02-17 1,700 $7.98 484,432 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2021.
  2. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $8.17 to $8.50 per share. The reporting person hereby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
  3. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $7.51 to $8.20 per share. The reporting person hereby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
  4. The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $7.95 to $8.00 per share. The reporting person hereby undertakes, upon request of the staff of the U.S. Securities and Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.